CSIMarket


Tyra Biosciences Inc   (TYRA)
Other Ticker:  
 


 

Tyra Biosciences Inc

TYRA's Financial Statements and Analysis



Tyra Biosciences Inc increased third quarter of 2023 net loss per share of $-0.49 compare to net loss per share of $-0.30 recorded in the same quarter a year ago a decrease compare to $-0.31 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.49 $  0 Mill
$-0.19     Unch.    



Tyra Biosciences Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Tyra Biosciences Inc is Expected to report next financial results on March 21, 2024.

More on TYRA's Income Statement



Tyra Biosciences Inc 's in thethird quarter of 2023 recorded net loss of $-21.152 million, an increase from net loss of $-12.509 million in III. Quarter a year ago.

Sequentially net loss advanced

More on TYRA's Growth

Tyra Biosciences Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-36 million, capital expenditures fell by -0.048247.92%, to $0 millions compare to same quarter a year ago

More on TYRA's Cash flow Statement


Tyra Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Tyra Biosciences Inc payed $ -1.13 cash per share, on a free-cash flow basis .

Book value fell by -7.48 % sequentially to $5.18 per share, -33.48% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.18 per share from $ 5.60.

Company issued 0.28 million shares or 0.66 % in Sep 30 2023.


More on TYRA's Dividends

 Market Capitalization (Millions) 830
 Shares Outstanding (Millions) 43
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Tyra Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Tyra Biosciences Inc had negative $ -1.13 cash flow per share, on a free-cash flow basis .

Book value fell by -7.48 % sequentially to $5.18 per share, -33.48% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.18 per share from $ 5.60.

Company issued 0.28 million shares or 0.66 % in Sep 30 2023.


More on TYRA's Balance Sheets

 Market Capitalization (Millions) 830
 Shares Outstanding (Millions) 43
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Tyra Biosciences Inc Earnings

Tyra Biosciences Inc's Surging Working Expenses Raise Concerns in Q3 2023 Earnings Season


As the July to September 30, 2023 reporting season resumes, the latest financial results have raised concerns for many investors, particularly in the Major Pharmaceutical Preparations industry. With the recent disclosure of a significant operating loss by Tyra Biosciences Inc during the third quarter of 2023, it is imperative to analyze the implications and potential road ahead for this company.
Tyra Biosciences Inc reported an operating loss of $-23.963 million, marking a significant deterioration from the $-13.645 million loss in the same quarter last year. This decline has provoked questions among investors about the company's ability to generate revenue in the near future. The absence of revenue...

Underdog Tyra Biosciences Inc Challenges the Status Quo with Narrowed Losses in Q2 2023

Trailing the big players in the Major Pharmaceutical Preparations industry, Tyra Biosciences Inc has emerged as a lesser-known entity that is making waves with its results. The company recently revealed an operating deficit of $-16.014 million for the second quarter of 2023. While the specific revenue figures have not been disclosed yet, comparing it to the company's performance in the second quarter of 2022 helps put the latest results into perspective. In the same quarter last year, Tyra recorded an operating deficit of $-15.428 million.
One positive aspect to note is that the losses have been trimmed compared to the previous year, indicating progress for the company. In the second quarter of 2023, the...

Tyra Biosciences Inc. Sees Significant Growth in Q1 2023 despite Operating Loss of $-14.334 Million

In the world of finance, the ...


Date modified: 2023-11-08T18:39:15+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com